PathoQuest Achieves CE Mark for the iDTECT™ Blood Test
PathoQuest, a biotechnology company spun out from Institut Pasteur, today announced CE marking for iDTECT™ Blood, the company's new clinical test offering a game-changing NGS-based metagenomics approach that improves the breadth of pathogen detection. Compared to the currently available solutions, iDTECT Blood, a proprietary sample-to-report test, provides clinicians a significantly improved method for detecting bacteria and viruses in blood samples from patients with suspected infections, especially immunocompromised patients.
"With this CE marking, PathoQuest will execute its global strategy and enter in early access programmes in selected countries." stated Helene Peyro-Saint-Paul, M.D., PathoQuest's Chief Medical Officer. "We believe iDTECT Blood will contribute to improved antibiotic stewardship and precision medicine strategies in infectious diseases, ultimately leading to better patient care."
Professor Olivier Lortholary, Professor and Chair of the Department of Infectious and Tropical iseases at Hôpital Necker-Enfants Malades, Paris, indicated that "In some clinical situations, especially when a patient is immunocompromised, culture and PCR (News - Alert) tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy. With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals (Paris, France) on a cohort of over 100 immuno-compromised patients."
"CE marking of the iDTECT Blood test is a major milestone for
PathoQuest. It validates the robustness of our sample-to-BioIT analysis
solution, driven by PathoQuest's proprietary iDTECT database and
software" stated Jean-Francois Brepson, PathoQuest's CEO.
To learn more about PathoQuest, visit www.pathoquest.com